Home › Companies › KYMERA THERAPEUTICS INC. › 2024-2025
Compiled from SEC Form N-PX filings and KYMERA THERAPEUTICS INC.’s Form 8-K, filed June 27, 2025 (Item 5.07 on EDGAR). Page generated October 25, 2026.
Meeting of June 25, 2025: 4 items on KYMERA THERAPEUTICS INC.’s Form 8-K, filed June 27, 2025: 2 approved · 2 without a stated outcome.
None.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Explore KYMERA THERAPEUTICS INC. in the interactive database Compare manager voting policies
These tallies are KYMERA THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 27, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Jeffrey Albers, J.D., MBA | 55,765,189 | -- | -- | 3,142,251 | 2,748,381 | 95% | Not verified | — |
| Elect Director: Felix J. Baker, Ph.D. | 51,745,887 | -- | -- | 7,161,553 | 2,748,381 | 88% | Not verified | — |
| 2. Non-Binding, Advisory Vote on Compensation of the Company's Named Executive Officers | 54,364,880 | 4,531,413 | 11,147 | -- | 2,748,381 | 92% | Approved | — |
| 3. Ratification of Appointment of the Company's Independent Registered Public Accounting Firm | 61,644,725 | 4,768 | 6,328 | -- | 0 | 99.9% | Approved | — |
Source: KYMERA THERAPEUTICS INC., Form 8-K, filed with the SEC on June 27, 2025 — read the filing on EDGAR.
Each item below shows how the 192 asset managers that disclosed a KYMERA THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 5 wordings of this item as funds reported it.
88% Majority: yes · of votes cast
Description as filed by funds: To elect two class II directors to our Board of Directors, each to serve until the 2028 Annual Meeting of Shareholders and until his successor has been duly elected and qualified, or until his earlier death, resignation or removal: Felix J. Baker, Ph.D.
KYMERA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Felix J. Baker, Ph.D.”): 51,745,887 for, 7,161,553 withheld, per its Form 8-K filed June 27, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 88% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 65 asset managers below reported 20,153,415 for, 1,280,898 withheld, 1,284,444 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 9,142,775 | 0 | 0 | 0 | For |
| T. Rowe Price | 4,957,425 | 0 | 0 | 0 | For |
| Fidelity | 3,060,220 | 0 | 0 | 17,284 | For |
| BlackRock | 0 | 0 | 1,168,188 | 0 | Abstain |
| Capital Group | 1,033,782 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 525,138 | 0 | 0 | 0 | For |
| MFS | 0 | 0 | 0 | 447,732 | Withhold |
| Charles Schwab | 386,609 | 0 | 0 | 0 | For |
| Prudential/PGIM | 274,195 | 0 | 0 | 4,494 | For |
| State Street | 726 | 0 | 0 | 248,648 | Withhold |
| Hartford | 237,696 | 0 | 0 | 0 | For |
| Equitable | 19,144 | 0 | 0 | 120,330 | Mixed |
| TIAA | 110,706 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 0 | 0 | 0 | 79,262 | Withhold |
| Pacific Life | 0 | 0 | 0 | 70,539 | Withhold |
| John Hancock | 49,943 | 0 | 16,839 | 0 | Mixed |
| Lincoln Financial | 0 | 0 | 0 | 65,919 | Withhold |
| Yiheng Capital Management, L.P. | 63,854 | 0 | 0 | 0 | For |
| Northwestern Mutual | 62,582 | 0 | 0 | 0 | For |
| Brighthouse | 47,057 | 0 | 0 | 5,795 | Mixed |
| QUANTITATIVE MASTER SERIES LLC | 0 | 0 | 52,004 | 0 | Abstain |
| Transamerica | 43,263 | 0 | 0 | 0 | For |
| Victory Capital | 839 | 0 | 0 | 39,981 | Withhold |
| Harbor ETF Trust | 30,959 | 0 | 0 | 0 | For |
| Global X | 28,302 | 0 | 0 | 0 | For |
Showing the 25 largest of 65 asset managers. See all 65 in the interactive database.
Combines 5 wordings of this item as funds reported it.
95% Majority: yes · of votes cast
Description as filed by funds: To elect two class II directors to our Board of Directors, each to serve until the 2028 Annual Meeting of Shareholders and until his successor has been duly elected and qualified, or until his earlier death, resignation or removal: Jeffrey Albers, J.D., MBA
KYMERA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Jeffrey Albers, J.D., MBA”): 55,765,189 for, 3,142,251 withheld, per its Form 8-K filed June 27, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 95% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 65 asset managers below reported 21,809,989 for, 854,124 withheld, 54,644 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 9,142,775 | 0 | 0 | 0 | For |
| T. Rowe Price | 4,957,425 | 0 | 0 | 0 | For |
| Fidelity | 3,077,504 | 0 | 0 | 0 | For |
| BlackRock | 1,168,188 | 0 | 0 | 0 | For |
| Capital Group | 1,033,782 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 525,138 | 0 | 0 | 0 | For |
| MFS | 0 | 0 | 0 | 447,732 | Withhold |
| Charles Schwab | 386,609 | 0 | 0 | 0 | For |
| Prudential/PGIM | 274,195 | 0 | 0 | 4,494 | For |
| State Street | 249,054 | 0 | 0 | 320 | For |
| Hartford | 237,696 | 0 | 0 | 0 | For |
| Equitable | 94,484 | 0 | 0 | 44,990 | Mixed |
| TIAA | 110,706 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 0 | 0 | 0 | 79,262 | Withhold |
| Pacific Life | 14,635 | 0 | 0 | 55,904 | Mixed |
| John Hancock | 49,943 | 0 | 16,839 | 0 | Mixed |
| Lincoln Financial | 34,700 | 0 | 0 | 31,219 | Mixed |
| Yiheng Capital Management, L.P. | 63,854 | 0 | 0 | 0 | For |
| Northwestern Mutual | 62,582 | 0 | 0 | 0 | For |
| Brighthouse | 47,057 | 0 | 0 | 5,795 | Mixed |
| QUANTITATIVE MASTER SERIES LLC | 52,004 | 0 | 0 | 0 | For |
| Transamerica | 43,263 | 0 | 0 | 0 | For |
| Victory Capital | 839 | 0 | 0 | 39,981 | Withhold |
| Harbor ETF Trust | 30,959 | 0 | 0 | 0 | For |
| Global X | 28,302 | 0 | 0 | 0 | For |
Showing the 25 largest of 65 asset managers. See all 65 in the interactive database.
Combines 10 wordings of this item as funds reported it.
92% Approved · of votes cast
Description as filed by funds: To approve, on a non-binding advisory basis, the compensation of our named executive officers; and
KYMERA THERAPEUTICS INC.’s own tally for this item (“2. Non-Binding, Advisory Vote on Compensation of the Company's Named Executive Officers”): 54,364,880 for, 4,531,413 against — passed, per its Form 8-K filed June 27, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 2 – Non-Binding, Advisory Vote on Compensation of the Company's Named Executive Officers The shareholders of the Company approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers.”
Support: 92% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 9,142,370 | 405 | 0 | 0 | For |
| T. Rowe Price | 4,957,425 | 0 | 0 | 0 | For |
| Fidelity | 3,077,504 | 0 | 0 | 0 | For |
| BlackRock | 1,168,188 | 0 | 0 | 0 | For |
| Capital Group | 0 | 1,033,782 | 0 | 0 | Against |
| MUTUAL FUND SERIES TRUST | 525,138 | 0 | 0 | 0 | For |
| MFS | 0 | 447,732 | 0 | 0 | Against |
| Charles Schwab | 386,609 | 0 | 0 | 0 | For |
| Prudential/PGIM | 1,284 | 277,405 | 0 | 0 | Against |
| State Street | 249,374 | 0 | 0 | 0 | For |
| Hartford | 237,696 | 0 | 0 | 0 | For |
| Equitable | 139,474 | 0 | 0 | 0 | For |
| TIAA | 110,706 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 79,262 | 0 | 0 | 0 | For |
| Pacific Life | 14,635 | 55,904 | 0 | 0 | Mixed |
| John Hancock | 66,782 | 0 | 0 | 0 | For |
| Lincoln Financial | 64,444 | 1,475 | 0 | 0 | For |
| Northwestern Mutual | 62,582 | 0 | 0 | 0 | For |
| Brighthouse | 47,058 | 0 | 5,794 | 0 | Mixed |
| QUANTITATIVE MASTER SERIES LLC | 52,004 | 0 | 0 | 0 | For |
| Transamerica | 43,263 | 0 | 0 | 0 | For |
| Victory Capital | 40,820 | 0 | 0 | 0 | For |
| Harbor ETF Trust | 30,959 | 0 | 0 | 0 | For |
| Global X | 0 | 28,302 | 0 | 0 | Against |
| AIG/SunAmerica | 26,969 | 0 | 0 | 0 | For |
Fund voting reports, all 64 managers: 20,716,357 for, 1,932,752 against, 5,794 abstained. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| T. Rowe Price | 6,564,519 | 0 | 0 | 0 | For |
| BAKER BROS. ADVISORS LP | 5,995,929 | 0 | 0 | 0 | For |
| Wellington | 5,390,449 | 0 | 0 | 0 | For |
| Atlas Venture Life Science Advisors, LLC | 4,896,462 | 0 | 0 | 0 | For |
| BVF INC/IL | 4,607,955 | 0 | 0 | 0 | For |
| Fidelity | 4,104,292 | 0 | 0 | 0 | For |
| Siren, L.L.C. | 2,829,980 | 0 | 0 | 0 | For |
| Avoro Capital Advisors LLC | 2,791,209 | 0 | 0 | 0 | For |
| BlackRock | 1,487,750 | 94 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,101,087 | 0 | 0 | 0 | For |
| State Street | 1,088,549 | 0 | 0 | 0 | For |
| Capital Research Global Investors | 0 | 1,033,782 | 0 | 0 | Against |
| Redmile Group, LLC | 0 | 983,413 | 0 | 0 | Against |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 593,000 | 0 | 0 | 0 | For |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 0 | 503,636 | 0 | 0 | Against |
| Rock Springs Capital Management LP | 464,449 | 0 | 0 | 0 | For |
| JENNISON ASSOCIATES LLC | 0 | 418,727 | 0 | 0 | Against |
| BRAIDWELL LP | 392,764 | 0 | 0 | 0 | For |
| Charles Schwab | 386,952 | 0 | 0 | 0 | For |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 263,673 | 0 | 0 | 0 | For |
| Northern Trust | 226,246 | 0 | 0 | 0 | For |
| UBS | 0 | 197,956 | 0 | 0 | Against |
| Janus Henderson | 149,214 | 0 | 0 | 0 | For |
| Foresite Capital Management VI LLC | 146,332 | 0 | 0 | 0 | For |
| Vanguard | 139,048 | 0 | 0 | 0 | For |
Institutional-manager reports, all 146 managers: 44,375,000 for, 3,783,974 against. Showing the 25 largest; see all in the interactive database.
99.9% Approved · of votes cast
Description as filed by funds: TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2025.
KYMERA THERAPEUTICS INC.’s own tally for this item (“3. Ratification of Appointment of the Company's Independent Registered Public Accounting Firm”): 61,644,725 for, 4,768 against — passed, per its Form 8-K filed June 27, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 3 – Ratification of Appointment of the Company's Independent Registered Public Accounting Firm The shareholders of the Company ratified the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 65 asset managers below reported 22,712,699 for, 264 against, 5,794 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 9,142,775 | 0 | 0 | 0 | For |
| T. Rowe Price | 4,957,425 | 0 | 0 | 0 | For |
| Fidelity | 3,077,504 | 0 | 0 | 0 | For |
| BlackRock | 1,168,188 | 0 | 0 | 0 | For |
| Capital Group | 1,033,782 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 525,138 | 0 | 0 | 0 | For |
| MFS | 447,732 | 0 | 0 | 0 | For |
| Charles Schwab | 386,609 | 0 | 0 | 0 | For |
| Prudential/PGIM | 278,689 | 0 | 0 | 0 | For |
| State Street | 249,374 | 0 | 0 | 0 | For |
| Hartford | 237,696 | 0 | 0 | 0 | For |
| Equitable | 139,474 | 0 | 0 | 0 | For |
| TIAA | 110,706 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 79,262 | 0 | 0 | 0 | For |
| Pacific Life | 70,539 | 0 | 0 | 0 | For |
| John Hancock | 66,782 | 0 | 0 | 0 | For |
| Lincoln Financial | 65,919 | 0 | 0 | 0 | For |
| Yiheng Capital Management, L.P. | 63,854 | 0 | 0 | 0 | For |
| Northwestern Mutual | 62,582 | 0 | 0 | 0 | For |
| Brighthouse | 47,058 | 0 | 5,794 | 0 | Mixed |
| QUANTITATIVE MASTER SERIES LLC | 52,004 | 0 | 0 | 0 | For |
| Transamerica | 43,263 | 0 | 0 | 0 | For |
| Victory Capital | 40,820 | 0 | 0 | 0 | For |
| Harbor ETF Trust | 30,959 | 0 | 0 | 0 | For |
| Global X | 28,302 | 0 | 0 | 0 | For |
Showing the 25 largest of 65 asset managers. See all 65 in the interactive database.
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 65,112,714 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 14.04% |
| 2 | T. Rowe Price | 7.61% |
| 3 | Fidelity | 4.73% |
| 4 | BlackRock | 1.79% |
| 5 | Capital Group | 1.59% |
| 6 | MUTUAL FUND SERIES TRUST | 0.81% |
| 7 | MFS | 0.69% |
| 8 | Charles Schwab | 0.59% |
| 9 | Prudential/PGIM | 0.43% |
| 10 | State Street | 0.38% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | T. Rowe Price | 10.08% |
| 2 | BAKER BROS. ADVISORS LP | 9.21% |
| 3 | Wellington | 8.28% |
| 4 | Atlas Venture Life Science Advisors, LLC | 7.52% |
| 5 | BVF INC/IL | 7.08% |
| 6 | Fidelity | 6.30% |
| 7 | Siren, L.L.C. | 4.35% |
| 8 | Avoro Capital Advisors LLC | 4.29% |
| 9 | BlackRock | 2.29% |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 1.69% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| Avoro Capital Advisors LLC | 10.33% | DEF14A |
| T. Rowe Price | 10.29% | 13F |
| Entities affiliated with BVF Partners L.P. | 10.02% | DEF14A |
| Entities affiliated with Baker Bros. Advisors LP | 9.23% | DEF14A |
| Felix Baker, Ph.D. | 9.23% | DEF14A |
| T. Rowe Price Investment Management, Inc. | 8.39% | 13G |
| Wellington Management Group LLP | 8.15% | DEF14A |
| BVF PARTNERS L P/IL | 8.04% | 13D |
| Vanguard Group | 8.03% | 13F |
| FMR LLC | 7.85% | DEF14A |
Percentages above are of 65,112,714 shares outstanding, as reported by KYMERA THERAPEUTICS INC. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from KYMERA THERAPEUTICS INC.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on October 25, 2026; a live search always shows the current data.
At KYMERA THERAPEUTICS INC.'s shareholder meeting held June 25, 2025, in the 2024-2025 proxy season, 192 asset managers reported how they voted on 4 ballot items in their SEC Form N-PX filings, covering 1,039 separate fund positions. On the most widely held item on that ballot — To approve, on a non-binding advisory basis, the compensation of our named executive officers… — KYMERA THERAPEUTICS INC.'s filing reports the proposal as approved, with 92% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: KYMERA THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 27, 2025.
KYMERA THERAPEUTICS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.
Download data (CSV): ballot items · votes by manager · column guide.